Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $8.4 million.

  • United Therapeutics' Gains from Investment Securities fell 8913.32% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $373.6 million, marking a year-over-year decrease of 318.74%. This contributed to the annual value of $400.6 million for FY2024, which is 2048.12% up from last year.
  • United Therapeutics' Gains from Investment Securities amounted to $8.4 million in Q3 2025, which was down 8913.32% from $238.6 million recorded in Q2 2025.
  • United Therapeutics' Gains from Investment Securities' 5-year high stood at $238.6 million during Q2 2025, with a 5-year trough of $2.3 million in Q2 2021.
  • For the 5-year period, United Therapeutics' Gains from Investment Securities averaged around $64.8 million, with its median value being $19.2 million (2021).
  • In the last 5 years, United Therapeutics' Gains from Investment Securities crashed by 8915.09% in 2021 and then soared by 27327.59% in 2022.
  • Over the past 5 years, United Therapeutics' Gains from Investment Securities (Quarter) stood at $23.2 million in 2021, then skyrocketed by 273.28% to $86.6 million in 2022, then rose by 11.55% to $96.6 million in 2023, then grew by 15.22% to $111.3 million in 2024, then crashed by 92.45% to $8.4 million in 2025.
  • Its last three reported values are $8.4 million in Q3 2025, $238.6 million for Q2 2025, and $15.3 million during Q1 2025.